NCT05761067 STICH-3.0 International Trial Consortium
| NCT ID | NCT05761067 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vastra Gotaland Region |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,800 participants |
| Start Date | 2022-09-14 |
| Primary Completion | 2029-09-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,800 participants in total. It began in 2022-09-14 with a primary completion date of 2029-09-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of the STICH 3.0 Study is to determine whether CABG is superior to PCI in terms of all-cause mortality at 5 years in patients with severe CAD and iLVSD. Individual patient data from similar national RCTs independently powered for different efficacy endpoints will be pooled, harmonized, and analyzed. The primary endpoint is all-cause mortality.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * LVEF ≤40% * Extensive coronary artery disease (typically defined as a British Cardiovascular Intervention Society jeopardy score of ≥6, on a scale from 0 to 12, with higher scores indicating greater extent of disease). Exclusion Criteria: * Decompensated heart failure requiring inotropic/adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ ventricular assist device therapy less than 48 hours prior to randomization; * Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) indicating the need for surgical repair/replacement; * Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy; * Pregnancy; * Circumstances likely to lead to poor treatment adherence; * STEMI within 72 hours; * PCI within 3 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05761067 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05761067 currently recruiting?
Yes, NCT05761067 is actively recruiting participants. Contact the research team at bjorn.redfors@wlab.gu.se for enrollment information.
Where is the NCT05761067 trial being conducted?
This trial is being conducted at Gothenburg, Sweden.
Who is sponsoring the NCT05761067 clinical trial?
NCT05761067 is sponsored by Vastra Gotaland Region. The trial plans to enroll 2,800 participants.